TG Therapeutics Inc
NASDAQ:TGTX

  • LAST PRICE
    23.3900
  • TODAY'S CHANGE (%)
    -0.4400 (-1.8464%)
  • Bid / Lots
    23.3500/ 1
  • Ask / Lots
    23.3900/ 7
  • Open / Previous Close
    23.7400 / 23.8300
  • Day Range
    23.3210
    24.4000
  • 52 Week Range
    6.4600
    26.4100
  • Volume
    2,189,307

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
TGTX
TG Therapeutics Inc
3.7B
39.0x
---
ADMA
ADMA Biologics Inc
4.2B
142.2x
---
TWST
Twist Bioscience Corp
2.8B
-11.8x
---
ARWR
Arrowhead Pharmaceuticals Inc
2.7B
-4.2x
---
AXSM
Axsome Therapeutics Inc
4.5B
-13.8x
---
ACLX
Arcellx Inc
4.1B
-79.4x
---
As of 2024-10-01

Company Information

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Contact Information

Headquarters
3020 Carrington Mill Blvd., Suite 475MORRISVILLE, NC, United States 27560-5435
Phone
212-554-4484
Fax
212-554-4531

Executives

Chairman of the Board, President, Chief Executive Officer
Michael Weiss
Chief Financial Officer, Treasurer, Corporate Secretary
Sean Power
Lead Independent Director
Laurence Charney
Independent Director
Yann Echelard
Independent Director
Kenneth Hoberman

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$3.7B
Revenue (TTM)
$346.7M
Shares Outstanding
154.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.21
EPS
$0.60
Book Value
$1.06
P/E Ratio
39.0x
Price/Sales (TTM)
10.6
Price/Cash Flow (TTM)
38.3x
Operating Margin
29.37%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.